0 of 9 questions completed
Questions:
You have already completed the assessment before. Hence you can not start it again.
Assessment is loading…
You must sign in or sign up to start the assessment.
You must first complete the following:
0 of 9 questions answered correctly
Your time:
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
The two FDA Approved CAR T-cells for relapsed or refractory large B-cell lymphomas are:
In the Zuma1 Study, “refractory” was defined as:
The median age of the diffuse large B-cell lymphoma (DLBCL) subjects in the ZUMA 1 trial was:
Risk Evaluation Mitigation Strategies (REMS) include all of the following except:
Foundation for the Accreditation of Cellular Therapy (FACT) accreditation is significant for all of the following reasons except:
During the waiting period between apheresis and infusion of CAR T-cells all of the following needs to take place except:
Prior to infusion of CAR T-cells:
During post CAR T-cell infusion monitoring the hospital staff (e.g nurse/Nurse practitioner) will:
CAR T-cell treated patients may be seen in: